ArticleRheumatology international2025
Prediction of relapses in patients with small vessel vasculitides: a multicenter cohort study on histopathological risk patterns.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of ANCA-associated vasculitis (AAV) has significantly improved, yet up to 40% of patients experience relapses, leading to worse long-term outcomes and organ damage. This multicenter cohort study investigated the prognostic value of histopathological patterns in renal AAV for predicting relapse risk and treatment response. We retrospectively analyzed 264 patients with newly diagnosed granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) with renal involvement recruited at four tertiary rheumatology and/or nephrology centers. Baseline clinical data, disease activity scores, and kidney biopsy findings were assessed. Patients were followed for at least twelve months. An overall relapse was defined as renewed disease activity requiring changes in maintenance therapy, initiation of a new induction regimen, or an increase in prednisone dosage > 10 mg/day. A severe relapse required new immunosuppressive induction therapy. After a median follow-up of twelve months the renal domain of the Birmingham Vasculitis Activity Score (BVAS) and its subcategories were evaluated. AAV patients with moderate-to-high (> 25%) interstitial fibrosis and tubular atrophy (IFTA) had a lower risk for both, overall and severe relapses. Severe relapses occurred more frequently in older and male patients. Furthermore, we identified glomerular sclerosis (≥ 50%) to be the strongest predictor for ongoing activity in the renal BVAS domain. Histopathological features do not only help to predict renal recovery and need for dialysis but also to forecast relapse risk and renal BVAS activity. Incorporating these patterns into clinical decision-making could enable more personalized therapy approaches, highlighting the need for prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.